The effect of desmopressin (DDAVP) on reducing postoperative blood loss after cardiac surgery has been studied in several randomized clinical trials with conflicting outcomes. Since most trials had insufficient statistical power to detect true differences in blood loss, we performed a meta-analysis of data from relevant studies. Seventeen randomized, double-blind, placebo-controlled trials were...

Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo. There was a significant decrease in micturition frequency in the 6 hour post-treatment period from 3.1 voids after placebo to 2.4 voids and a significant reduction in urinary volume after desmopressin. Eighty ...

Sanchis-Gomar F, Martinez-Bello VE, Derbre F, García-López E, García-Valles R, Brioche T, Ferrando B, Ibañez-Sania S, Pareja-Galeano H, Gomez-Cabrera MC, Viña J. Rapid hemodilution induced by desmopressin after erythropoietin administration in humans. J. Hum. Sport Exerc. Vol. 6, No. 2, 2011. We have shown that treatment with demospressin has a very effective hemodilution effect in healthy huma...

PURPOSE To investigate the type of nocturia and concomitant voiding dysfunction (VD) and the effect of desmopressin treatment on nocturia in women. MATERIALS AND METHODS We reviewed 84 women who experienced more than 2 nocturia episodes as recorded on a pretreatment frequency volume chart and who were treated with desmopressin. All patients underwent history taking, physical examination, urin...

SUMMARY Hypothermia and acidosis lead to an impairment of coagulation. It has been demonstrated that desmopressin improves platelet function under hypothermia. We tested platelet function ex vivo during hypothermia and acidosis. Blood samples were taken from 12 healthy subjects and assigned as follows: normal pH, pH 7.2, and pH 7.0, each with and without incubation with desmopressin. Platelet a...

BACKGROUND Intranasal desmopressin has been used extensively to treat primary nocturnal enuresis. While it has proven to be a safe, effective agent for many who are affected by this condition, the potential for complications exists. OBJECTIVES To report a case of severe hyponatremia associated with a generalized tonic-clonic seizure in a 10-year-old boy who had been receiving intranasal desmo...

Drs E J SIMMONDS, M J MAHONY, and J M LITTLEWOOD (Regional Cystic Fibrosis Unit, St James's Hospital, Leeds LS9 7TF) write: Desmopressin has been advocated as a treatment for nocturnal enuresis. We report on a child with cystic fibrosis who developed water intoxication while being treated with desmopressin. The patient, a girl aged 13 years, had made good progress apart from recurrent nasal pol...

conclusions there is no significant difference between monotherapy with desmopressin, imipramine or oxybutynin in children with enuresis. however, oxybutynin showed a higher response rate and a lower relapse rate compared to other medications. more clinical trials with a larger sample size are needed to clarify these uncertainties. results children in the oxybutynin group showed a slightly high...

To determine the role of von Willebrand factor (vWF) in adhesion of sickle (SS) erythrocytes in microvascular flow conditions, we have perfused the ex vivo mesocecum vasculature of the rat with desmopressin, an analogue of vasopressin that causes the release of endothelial vWF. Analysis of vWF in the venous effluent of the isolated vasculature showed mainly the presence of extra-large molecular...

The present study aimed to evaluate the clinical efficacy and safety of combination therapy comprising desmopressin plus anticholinergic agent compared with desmopressin alone for children with nocturnal enuresis (NE). A meta-analysis of 8 eligible studies was performed to analyze the effects of desmopressin plus anticholinergic agent combination therapy and desmopressin monotherapy in the trea...